2. Academic Validation
  3. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

  • Eur J Clin Pharmacol. 2011 Apr;67(4):333-346. doi: 10.1007/s00228-011-1006-7.
Natig Gassanov 1,  Nasser Semmo 2,  Mariam Semmo 3,  Amir M Nia 1,  Uwe Fuhr 4,  Fikret Er 5
Affiliations

Affiliations

  • 1 Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
  • 2 Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
  • 3 Department of Nephrology, University Hospital Freiburg, Freiburg, Germany.
  • 4 Department of Pharmacology, University of Cologne, Cologne, Germany.
  • 5 Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. fikret.er@uk-koeln.de.
PMID: 21327910 DOI: 10.1007/s00228-011-1006-7
Abstract

Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.

Figures